
Aarti Pharma Q1 FY25 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 2
Margin
Category 3
Fundraise
N/A
Order
Yes
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 2- CDMO/CMO business expects strong growth of 25% to 30% year-on-year in FY25 driven by increased inquiries and projects due to US Biosecure Act and China Plus One strategies.
- Expansion projects like Atali facility commissioning by Q4 FY25 will add 400-500 KL capacity, increasing capacity by about 25-30%, supporting future demand surge.
- Xanthine segment capacity is being expanded to 9000 MT by early FY26, addressing demand growth.
- Semi-commercial block at Vapi site operational in Q2 FY25 will enable small to medium batch size productions.
- Despite competition in Xanthine prices, export share grew to 57% this quarter, indicating volume growth potential.
- The Company aims for consolidated EBITDA growth of 10%-12% in FY25 and a long-term annual growth target of approximately 15%.
- Multi-stage CDMO projects' growth expected as more projects move from early to commercial stages.
See what Aarti Pharma management said on margin guidance — free account, 30 seconds.
Fundraise plans
- The transcript does not mention any current or planned fundraising through debt or equity.
- No specific details or discussions about raising funds via equity or debt instruments were provided during the Q1 FY25 earnings call.
- The focus was primarily on capacity expansions (Xanthine project, Atali project) and operational updates funded through internal accruals or ongoing CAPEX plans.
- Total CAPEX guidance for FY25 is around Rs. 500-550 crores, including Rs. 150 crores for Xanthine and Rs. 375 crores for the Atali project, with no mention of external fundraising.
- Management has not indicated any intentions to raise additional capital through the markets as of this call.
See what Aarti Pharma management said on order book — free account, 30 seconds.
Capex plans
YesTrack Aarti Pharma — get its next earnings analysis in your feed
How does Aarti Pharma rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does Aarti Pharma rank in Pharmaceuticals & Biotechnology?
Compare Aarti Pharma against every Pharmaceuticals & Biotechnology company (Q1 FY25) on revenue, margins and earnings-call signals.
Continue your research
What Aarti Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lasa Supergeneri (Q2 FY27)
306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra
- Themis Medicare (Q2 FY27)
Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q
- Panacea Biotec (Q2 FY27)
September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Biofil Chemicals (Q2 FY27)
Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem